CLOs on the Move

CTI Clinical Trial and Consulting Services

www.ctifacts.com

 
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI`s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.ctifacts.com
  • 100 E. RiverCenter Boulevard
    Covington, KY USA 41011
  • Phone: 513.598.9290

Executives

Name Title Contact Details
Ian Hennessey
General Counsel Profile
Joan Gates
Chief Legal and Risk Management Officer Profile
Joan Gates
Vice President and General Counsel Profile
Elizabeth Fox
Corporate Counsel Profile
Scott Batty
Vice President, Global Scientific and Regulatory Affairs Profile

Similar Companies

Medicare Rights Center

Medicare Rights Center is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ram Medical Inc

Ram Medical Inc is a Wayne, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Acuity Medical Systems

Acuity Medical Systems is a Wayzata, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Vantage Oncology

Vantage Oncology is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Manhattan Beach, CA. To find more information about Vantage Oncology, please visit www.vantageoncology.com

Avaxia Biologics

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.